+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-a4ß7 Integrin Monoclonal Antibody Market - Global Forecast 2026-2032- Product Image
Anti-a4ß7 Integrin Monoclonal Antibody Market - Global Forecast 2026-2032- Product Image
New

Anti-a4ß7 Integrin Monoclonal Antibody Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 186 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118069
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Anti-α4β7 Integrin Monoclonal Antibody Market is advancing rapidly, shaped by growing clinical differentiation, evolving delivery options, and strategic engagement across the healthcare ecosystem. Senior decision-makers navigating this landscape must align operational efficiency, supply flexibility, and payer strategy to realize substantial long-term value from gut-selective integrin inhibitors.

Market Snapshot: Anti-α4β7 Integrin Monoclonal Antibody Market

The market for anti-α4β7 integrin monoclonal antibodies is poised for robust growth, progressing from USD 3.12 billion in 2025 to USD 3.43 billion in 2026, with projections reaching USD 6.12 billion by 2032 and a compound annual growth rate (CAGR) of 10.08%. This expansion reflects therapeutic advances, enhanced delivery technology, and evolving payer models, signaling strong momentum amid a complex regulatory and commercial landscape.

Scope & Segmentation

This report delivers a multidimensional analysis covering clinical utility, distribution formats, age cohorts, and care models, enabling decision-makers to align product and commercialization strategies effectively. Market segmentation is structured as follows:

  • Indication Subtypes: Crohn's Disease, Indeterminate Colitis, Microscopic Colitis, Ulcerative Colitis, with further detail across colonic, ileal, ileocolonic, left-sided colitis, pancolitis, and proctitis presentations.
  • Administration Routes: Intravenous infusion, subcutaneous injection, including formats that support supervised and at-home administration.
  • Therapeutic Lines: First, second, and third-line use, segmented by prior exposure and therapeutic sequence.
  • Distribution Pathways: Hospital pharmacy (inpatient/outpatient), retail pharmacy (chain/independent), specialty pharmacy (hospital-affiliated/independent).
  • Age Cohorts: Adult, geriatric, pediatric populations, each requiring tailored clinical and formulation approaches.
  • Dosage Form Preferences: Autoinjector, prefilled syringe, single-dose vial, reflecting patient and operational needs.
  • Regional Markets: Americas, Europe, Middle East & Africa, Asia-Pacific; each region defined by unique regulatory, payer, and infrastructure realities.

Key Takeaways: Strategic Insights Driving Adoption

  • Therapeutic differentiation is critical for targeting disease subtypes and aligning mechanism of action with patient presentation.
  • Convenience-focused innovations, such as autoinjectors and self-administered options, are increasing patient adherence and retention.
  • Collaboration among manufacturers, specialty pharmacies, and contract partners is strengthening access while optimizing manufacturing and distribution resilience.
  • Real-world evidence and patient-reported outcomes are gaining priority in payer contracting and reimbursement negotiations, influencing formulary favorability.
  • Segmentation by disease phenotype and route of administration enables nuanced positioning and tailored support programs across clinical settings.
  • Regional adaptation remains essential, as differences in regulatory guidance and healthcare infrastructure influence commercialization and patient access globally.

Tariff Impact on Biologics Supply Chains

Recent shifts in trade policy and tariff structures have notably affected raw material procurement and cross-border manufacturing for integrin-targeted biologics. Stakeholders are reassessing global sourcing by qualifying new suppliers, localizing production where possible, and balancing inventory strategies to offset import duties and logistical bottlenecks. Increased coordination is required to address regulatory complexity and to ensure stable supply chains in fluctuating policy environments. Partnerships with regional manufacturers and distributors are pivotal in supporting cost management and distribution reliability.

Methodology & Data Sources

Research for this analysis integrates peer-reviewed literature, regulatory filings, and clinical trial registries with primary interviews from clinicians, payer specialists, supply chain, and distribution leaders. Findings are validated through expert triangulation and a structured segmentation framework, ensuring robust, actionable insights for commercialization planning and investment decisions.

Why This Report Matters

  • Aligns clinical, operational, and commercial strategies to accelerate the adoption of gut-selective integrin inhibitors.
  • Enables executive stakeholders to clarify opportunity sizing and mitigate risks tied to market access, delivery, and supply disruptions.
  • Provides an evidence-based roadmap for targeting high-value patient cohorts, streamlining distribution, and meeting diverse stakeholder incentives.

Conclusion

Success in the anti-α4β7 integrin monoclonal antibody market hinges on integrating clinical innovation, agile delivery, and sustainable supply chains. By leveraging robust segmentation and adapting to regional and policy dynamics, organizations can maximize adoption and create consistent, high-value outcomes across healthcare settings.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Indication
8.1. Crohn's Disease
8.1.1. Colonic
8.1.2. Ileal
8.1.3. Ileocolonic
8.2. Indeterminate Colitis
8.3. Microscopic Colitis
8.4. Ulcerative Colitis
8.4.1. Left-Sided Colitis
8.4.2. Pancolitis
8.4.3. Proctitis
9. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Administration Route
9.1. Intravenous Infusion
9.2. Subcutaneous Injection
10. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Line Of Therapy
10.1. First Line
10.2. Second Line
10.3. Third Line And Beyond
11. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Patient Age Group
11.1. Adult
11.2. Geriatric
11.3. Pediatric
12. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Dosage Form
12.1. Autoinjector
12.2. Prefilled Syringe
12.3. Single Dose Vial
13. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Anti-a4ß7 Integrin Monoclonal Antibody Market
17. China Anti-a4ß7 Integrin Monoclonal Antibody Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abcam
18.6. ACROBiosystems
18.7. Aladdin Scientific
18.8. Biorbyt
18.9. Bioss Inc.
18.10. BosterBio
18.11. Creative Diagnostics
18.12. GeneTex
18.13. ichorbio
18.14. Leinco Technologies
18.15. MyBioSource.com
18.16. Novus Biologicals
18.17. OriGene Technologies
18.18. R&D Systems
18.19. Santa Cruz Biotechnology, Inc.
18.20. Selleck Chemicals
18.21. Sino Biological
18.22. Thermo Fisher Scientific
18.23. United States Biological
List of Figures
FIGURE 1. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COLONIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COLONIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COLONIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEOCOLONIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEOCOLONIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEOCOLONIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDETERMINATE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDETERMINATE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY MICROSCOPIC COLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY MICROSCOPIC COLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY MICROSCOPIC COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LEFT-SIDED COLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LEFT-SIDED COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PANCOLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PANCOLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PANCOLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PROCTITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PROCTITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PROCTITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 105. EUROPE ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. EUROPE ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 107. EUROPE ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 108. EUROPE ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 109. EUROPE ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 110. EUROPE ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 112. EUROPE ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 121. AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 123. AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 124. AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 125. AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 126. AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 127. AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 128. AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. ASEAN ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. ASEAN ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 140. ASEAN ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 141. ASEAN ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 142. ASEAN ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 143. ASEAN ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 144. ASEAN ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 145. ASEAN ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 146. GCC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GCC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 148. GCC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 149. GCC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 150. GCC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 151. GCC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 152. GCC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 153. GCC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 162. BRICS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. BRICS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 164. BRICS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 165. BRICS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 166. BRICS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 167. BRICS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 168. BRICS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 169. BRICS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 170. G7 ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. G7 ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 172. G7 ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 173. G7 ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 174. G7 ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 175. G7 ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 176. G7 ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 177. G7 ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 178. NATO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 179. NATO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 180. NATO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 181. NATO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 182. NATO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 183. NATO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 184. NATO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 185. NATO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 189. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 190. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 191. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 192. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 193. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 195. CHINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 196. CHINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 197. CHINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2032 (USD MILLION)
TABLE 198. CHINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
TABLE 199. CHINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 200. CHINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 201. CHINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 202. CHINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)

Companies Mentioned

  • Abcam
  • ACROBiosystems
  • Aladdin Scientific
  • Biorbyt
  • Bioss Inc.
  • BosterBio
  • Creative Diagnostics
  • GeneTex
  • ichorbio
  • Leinco Technologies
  • MyBioSource.com
  • Novus Biologicals
  • OriGene Technologies
  • R&D Systems
  • Santa Cruz Biotechnology, Inc.
  • Selleck Chemicals
  • Sino Biological
  • Thermo Fisher Scientific
  • United States Biological

Table Information

Report AttributeDetails
No. of Pages186
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.43 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.12 Billion
Compound Annual Growth Rate10.0%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA - Product Image

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

  • Report
  • 84 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032 - Product Image

Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Antibody Therapeutics Market - Global Strategic Business Report - Product Image

Antibody Therapeutics Market - Global Strategic Business Report

  • Report
  • 577 Pages
  • Global
From
Anti-amyloid-ß Monoclonal Antibodies Market - Global Forecast 2026-2032 - Product Image

Anti-amyloid-ß Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Anti-CD20 Monoclonal Antibodies (MAbs) Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Anti-CD20 Monoclonal Antibodies (MAbs) Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.